Florida is currently home to 3755 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Miami, Tampa, Jacksonville and Orlando. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Single-Arm Comprehensive Ablative Bridging Irradiation I Prior to CD19 CAR-T In High-Risk R/R LBCL
NCT06104592
Recruiting
This is a phase 2, single-arm, open-label study to evaluate the safety and efficacy of comprehensive bridging radiation therapy prior to CD19 CAR T-cell therapy for large B-cell lymphoma patients with bulky disease, defined as any lesion ≥5 cm.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/12/2025
Locations: Moffitt Cancer Center, Tampa, Florida
Conditions: Large B-cell Lymphoma, Relapsed Non-Hodgkin Lymphoma
Register for Updates
ImpaCt Of Shiftwork on METabolic Flexibility and Skeletal Muscle Clocks
NCT05820490
Recruiting
The purpose of this study is to determine the impact of real-world shiftwork on metabolic flexibility.
Gender:
ALL
Ages:
Between 21 years and 45 years
Trial Updated:
03/12/2025
Locations: AdventHealth Translational Research Institute, Orlando, Florida
Conditions: Metabolic Health
Register for Updates
A First in Human Dose Escalation of Dendritic Cell Vaccine (DCV)
NCT05809752
Recruiting
The purpose of this study is to learn about the effects of the study treatment, Dendritic Cell Vaccine (DCV), to find the highest dose of the study treatment that can be given safely to Breast Cancer patients with Leptomeningeal Disease
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/12/2025
Locations: Moffitt Cancer Center, Tampa, Florida
Conditions: Leptomeningeal Disease, Triple Negative Breast Cancer, HER2-positive Breast Cancer
Register for Updates
A Trial to Learn How the Combination of Fianlimab With Cemiplimab and Chemotherapy Works Compared With Cemiplimab and Chemotherapy for Treating Adult Patients With Advanced Non-small Cell Lung Cancer
NCT05800015
Recruiting
This study is researching an investigational drug called fianlimab (also called REGN3767) with two other medications called cemiplimab and chemotherapy, individually called a "study drug" or collectively called "study drugs". 'Investigational' means that the study drug is not approved for use outside of this study by any Health Authority. Examples of chemotherapy drugs include the following: Paclitaxel plus carboplatin, and Pemetrexed plus cisplatin. The study is being conducted in patients who... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/12/2025
Locations: Clermont Oncology Center, Clermont, Florida
Conditions: Non-small Cell Lung Cancer
Register for Updates
A Study to Learn About the Safety of BIIB091 and Its Effect on Brain Inflammation When Taken Alone or With Diroximel Fumarate (DRF) in Adults With Relapsing Forms of Multiple Sclerosis (MS)
NCT05798520
Recruiting
In this study, researchers will learn more about a study drug called BIIB091 in participants with MS who may be experiencing relapses. It is a 2-part study. In Part 1, one set of participants will take either BIIB091 or diroximel fumarate (DRF). In Part 2, a different set of participants will take either a combination of BIIB091 and DRF or DRF alone. The goal of the study is to learn more about the safety of BIIB091 and to compare the effects of the study drug when taken alone or together with... Read More
Gender:
ALL
Ages:
Between 18 years and 55 years
Trial Updated:
03/12/2025
Locations: University of Miami Miller School of Medicine, Miami, Florida
Conditions: Relapsing Forms of Multiple Sclerosis
Register for Updates
Safety and Efficacy of NMD670 in Ambulatory Adult Patients With Type 3 Spinal Muscular Atrophy
NCT05794139
Recruiting
The purpose of this study is to evaluate the efficacy, safety, tolerability and pharmacokinetics of NMD670 in the treatment of ambulatory adults with spinal muscular atrophy type 3
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
03/12/2025
Locations: UF Fixel Institute for Neurological Diseases, Gainesville, Florida
Conditions: Spinal Muscular Atrophy
Register for Updates
A Study of DB-OTO, an Adeno-associated Virus (AAV) Based Gene Therapy, in Children/Infants With Hearing Loss Due to Otoferlin Mutations
NCT05788536
Recruiting
Regeneron is conducting a study of an investigational new drug called DB-OTO. DB-OTO is a gene therapy that is being developed to treat children who have hearing loss due to changes in the otoferlin gene. The purpose of this study is to: * Learn about the safety of DB-OTO * Determine how well DB-OTO is tolerated (does not cause ongoing discomfort) * Evaluate the efficacy of DB-OTO (how well DB-OTO works)
Gender:
ALL
Ages:
17 years and below
Trial Updated:
03/12/2025
Locations: Nemours Children s Clinic, Jacksonville, Florida
Conditions: Congenital Hearing Loss Secondary to Biallelic Mutations of the Otoferlin Gene (OTOF)
Register for Updates
Itacitinib Pre-modulation in DLBCL Receiving CAR T Cell Therapy
NCT05757219
Recruiting
The purpose of the study is to assess the safety and efficacy of once daily itacitinib oral administration in participants with diffuse large B-cell lymphoma (DLBCL) who will receive CAR-T cell therapy with axicabtagene ciloleucel (axi-cel).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/12/2025
Locations: Moffitt Cancer Center, Tampa, Florida
Conditions: Diffuse Large B Cell Lymphoma
Register for Updates
Olaparib in Combination With Pembrolizumab for Advanced Uveal Melanoma
NCT05524935
Recruiting
This is a prospective phase II multi-center trial of the combination of the PARP inhibitor olaparib with the immune checkpoint inhibitor pembrolizumab in advanced uveal melanoma.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/12/2025
Locations: Moffitt Cancer Center, Tampa, Florida
Conditions: Uveal Melanoma, Ocular Melanoma
Register for Updates
Adoptive T Cell Therapy Following HER2-Pulsed Dendritic Cell Vaccine & Pepinemab /Trastuzumab in Patients w/ Metastatic HER2+ Breast Cancer
NCT05378464
Recruiting
The purpose of this study is to test the safety of Adoptive T-Cell therapy following the Dendritic Cell (DC1) study vaccine given in combination with pepinemab added to standard of care therapy, trastuzumab to help people with HER2 positive breast cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/12/2025
Locations: Moffitt Cancer Center, Tampa, Florida
Conditions: HER2-positive Breast Cancer
Register for Updates
Nicotinamide Riboside Clinical Trial for GWI
NCT05243290
Recruiting
In this multi-site trial, we will use a randomized, double-blind, placebo-controlled study design to test whether 300 mg of Nicotinamide Riboside (NR) can achieve the primary objective of increasing plasma NAD+ levels in participants with Gulf War Illness (GWI).
Gender:
ALL
Ages:
Between 47 years and 70 years
Trial Updated:
03/12/2025
Locations: Nova Southeastern University, Fort Lauderdale, Florida
Conditions: Gulf War Illness
Register for Updates
Binimetinib Plus Belinostat for Subjects With Metastatic Uveal Melanoma
NCT05170334
Recruiting
This research study is investigating Binimetinib and Belinostat in participants with metastatic uveal melanoma. The research study will test the study drugs to see if the combination of binimetinib and belinostat can make tumors shrink or stop growing.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/12/2025
Locations: Moffitt Cancer Center, Tampa, Florida
Conditions: Metastatic Uveal Melanoma
Register for Updates